Trials / Completed
CompletedNCT01251159
Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid Leukemia
Somatic Mutations in Stem and Progenitor Cells in AML
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (actual)
- Sponsor
- ECOG-ACRIN Cancer Research Group · Network
- Sex
- All
- Age
- 16 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Studying samples of bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is studying bone marrow samples from patients with acute myeloid leukemia.
Detailed description
OBJECTIVES: * To rigorously examine fractionated hematopoietic stem and progenitor cells from patients with acute myeloid leukemia (AML). * To define somatic mutations occurring in de novo AML, including the FLT3-ITD, CEBPA, NPM1, TET2, ASXL1, IDH1, and IDH2 mutations. * To examine what cellular compartments (LT-HSC, ST-HSC, CMP, GMP, and MEP) contain the selected mutations and in what order those mutations occur. OUTLINE: Archived bone marrow specimens are analyzed for sequencing and detection of mutations by Sanger-based resequencing of PCR amplicons. Results are then compared with the results of age-matched healthy controls.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | mutation analysis | |
| GENETIC | polymerase chain reaction | |
| OTHER | immunologic technique | |
| OTHER | laboratory biomarker analysis |
Timeline
- Start date
- 2009-05-15
- Primary completion
- 2009-06-15
- Completion
- 2009-06-15
- First posted
- 2010-12-01
- Last updated
- 2017-05-17
Source: ClinicalTrials.gov record NCT01251159. Inclusion in this directory is not an endorsement.